Aerbio raises significant funding from Chr. Olesen Group and other investors, and enters major strategic agreement

The Danish biotech company Aerbio has just closed an oversubscribed bridge loan, providing the company with a substantial multi-million Euro investment from a group of investors, including the international distributor of proteins and ingredients, Chr. Olesen Group.

There is more positive news from Aerbio, who have received a significant multi-million Euro injection. The funds come from a bridge loan recently closed by the company, with the final amount exceeding the original target.

“We are very pleased with the strong support from both existing and new investors,” says Lars Topholm, Chairman of Aerbio.

Aerbio produces high-quality protein using a patented fermentation technology, where CO2​ and hydrogen are the primary ingredients. The technology can replace more conventional protein sources and thereby contribute to rainforest preservation and improvement of the global CO2​ balance. The company’s test facility in the Netherlands has demonstrated high efficiency and operational reliability for more than a year.

This has made Aerbio an obvious investment opportunity for Chr. Olesen Group, one of the contributors to the bridge loan. Chr. Olesen Group sells proteins and ingredients for animal feed, food, and the pharmaceutical industry, generating several billion Danish kroner annually.

“Aerbio’s technology is unique. It has the potential to change the world and gives the word ‘recycling’ an entirely new dimension. We are proud to invest in a company like Aerbio, which is capable of converting CO2​ into animal feed and food,” says Mads Chr. Olesen, CEO and owner of Chr. Olesen Group.

Poised for a quantum leap

The funds from the bridge loan will, among other things, be used in connection with a significant strategic agreement with an international partner, as well as to support Aerbio’s operations

The strategic agreement will accelerate Aerbio’s plans, including a stock exchange listing, and will significantly reduce key risks. The agreement provides access to valuable know-how, patents, and key personnel, enabling the rapid design and construction of highly efficient demonstration and commercial-scale facilities. “We are on the verge of a quantum leap and are now moving much faster towards building our first industrial-scale commercial plant,” says Aerbio CEO Kaspar Kristiansen.

Aerbio expects to have its first commercial production facility operational in 2027. The first full-scale commercial plant is planned to be operational in 2030 and will produce several hundred thousand tons of protein annually.

Negotiations on Multiple Commercial Agreements

Over the past few years, Aerbio has conducted numerous trials and tests of its protein product PROTONR◯ in feed for various types of fish and pets. The results have been highly convincing. These results have generated strong interest from global feed producers.

“We expect to enter into several major agreements before the end of the year,” says CEO Kaspar Kristiansen.

In the coming weeks, Aerbio will begin raising funds for its first commercial plant. Chr. Olesen Group has committed to participating as an investor. The two companies will also soon begin discussions on developing a business partnership.

For further information, please contact:

Press@aer.bio